Company: NCEL
Filing Date: 2025-02-05
Form Type: F-3
Source: 0001213900-25-010223
Chunk: 41

Company: NewcelX Ltd.
Filing Date: 2025-02-05
Form: F-3
Chunk 41
---
 below and the full risks described under the caption “Item 3. Key Information - D. Risk Factors” in the 2023 Annual Report, which is incorporated by reference in this prospectus, before deciding whether to invest in the Common Shares. The risks described below are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially and adversely affect our business operations. If any of these risks actually occur, our business, financial condition, operating results or cash flows could be materially adversely affected. This could cause the trading price of the Common Shares to decline, and you may lose all or part of your investment.

Risks Related to the Merger

Failure to consummate the Merger as currently contemplated or at all could adversely affect the price of Common Shares or Kadimastem Ordinary Shares and the future business and financial results of NLS and Kadimastem.

The Merger may be consummated on terms different than those contemplated by the Merger Agreement, or the Merger may not be consummated at all. If the Merger is not completed, or is completed on different terms from those contemplated by the Merger Agreement, NLS and Kadimastem could be adversely affected and subject to a variety of risks associated with the failure to consummate the Merger, or to consummate the Merger as contemplated by the Merger Agreement, including the following:

| ● | the NLS shareholders and                                                                            
 the Kadimastem shareholders may be prevented from realizing the anticipated benefits of the Merger; |

| ● | the market price of our                                                 
 Common Share or Kadimastem Ordinary Shares could decline significantly; |

| ● | reputational harm due to                                                     
 the adverse perception of any failure to successfully consummate the Merger; |

| ● | incurrence of substantial                                                                                                               
 costs relating to the proposed Merger, such as legal, accounting, financial advisor, filing, printing and mailing fees, and, in certain 
 cases, the payment by NLS of a termination fee to NLS; and                                                                              |

| ● | the attention of NLS’                                                                                                 
 and Kadimastem’s management and employees may be diverted from their day-to-day business and operational matters as a 
 result of efforts relating to attempting to consummate the Merger.                                                    |

Any delay in the consummation of the Merger or any uncertainty about the consummation of the Merger on terms other than those contemplated by